Results from a Phase 1 Study Assessing the Pharmacokinetics of the Aldosterone Synthase Inhibitor Baxdrostat in Participants with Varying Degrees of Renal Function

Baxdrostat is a selective small‐molecule aldosterone synthase inhibitor in development for treatment of hypertension and chronic kidney disease. This phase 1, open‐label, parallel‐group study assessed the safety and pharmacokinetics (PK) of baxdrostat in participants with varying degrees of renal function. Participants were enrolled into control (estimated glomerular filtration rate [eGFR] ≥60 mL/min), moderate to severe renal impairment (eGFR 15‐59 mL/min), or kidney failure (eGFR